Cancer of the Prostate
55
6
9
31
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
14 trials with published results (25%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.1%
5 terminated out of 55 trials
86.1%
-0.4% vs benchmark
9%
5 trials in Phase 3/4
45%
14 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 31 completed trials
Clinical Trials (55)
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Low-Count Quantitative SPECT for Men Treated With Radium-223
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
Investigation of Impact of AI on Prostate Cancer Workflow
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Proton Boost in Prostate Cancer
A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
MRI/Ultrasound Fusion Guided Prostate Cryotherapy
Hemi-Ablative Prostate Brachytherapy
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC